In a significant move to consolidate its leadership in the rare disease sector, BioMarin Pharmaceutical Inc. announced on Thursday an exclusive worldwide license agreement with South Korean firms GC Biopharma and Hanmi Pharmaceutical. The deal secures BioMarin the global rights to HM15421/GC1134A, an investigational, long-acting enzyme replacement therapy (ERT) currently in clinical development for the treatment of Fabry disease. This acquisition represents a major strategic pivot for the San Rafael, California-based biotechnology giant, as it seeks to offer a more comprehensive suite of treatment options for patients suffering from this debilitating lysosomal storage disorder.
Under the terms of the agreement, BioMarin will pay an upfront fee of $70 million to GC Biopharma and Hanmi Pharm. The deal structure also includes potential milestone payments totaling up to $405 million, contingent upon the successful achievement of specific clinical development and commercialization goals. Furthermore, the South Korean partners remain eligible to receive tiered royalties on future net sales of the product. While BioMarin assumes global responsibility for the drug’s development and commercialization, GC Biopharma and Hanmi Pharm will retain their rights to the therapy within the South Korean market.
The Strategic Terms of the Licensing Agreement
The acquisition of HM15421/GC1134A is timed to capitalize on BioMarin’s existing infrastructure in the enzyme replacement therapy space. By integrating this next-generation candidate into its pipeline, BioMarin is effectively doubling down on its commitment to the Fabry disease community. The deal follows the company’s massive $4.8 billion acquisition of Amicus Therapeutics, which closed earlier in 2025 and brought the oral chaperone therapy Galafold (migalastat) into BioMarin’s commercial portfolio.
BioMarin’s decision to pursue a long-acting ERT reflects a deep understanding of the current limitations in Fabry care. While Galafold has been a commercial success, its use is restricted to patients with "amenable" mutations—those whose specific genetic variant allows the drug to stabilize the endogenous alpha-galactosidase A (alpha-Gal A) enzyme. Analysts estimate that approximately 60% to 70% of the total Fabry disease population does not possess these amenable mutations, leaving a vast majority of patients reliant on traditional, more burdensome intravenous infusions. HM15421/GC1134A is intended to bridge this gap, providing a viable option for those who cannot benefit from chaperone therapy.
Understanding Fabry Disease and the Unmet Medical Need
Fabry disease is a rare, X-linked inherited lysosomal storage disorder caused by mutations in the GLA gene. These mutations result in a deficiency or total absence of the enzyme alpha-galactosidase A. Under normal physiological conditions, this enzyme is responsible for breaking down globotriaosylceramide (Gb3), a type of sphingolipid. Without sufficient enzyme activity, Gb3 accumulates progressively within the lysosomes of various cell types, particularly in the vascular endothelium, heart, and kidneys.
The clinical manifestations of Fabry disease are diverse and often life-threatening. Early symptoms typically include episodes of severe burning pain in the extremities (acroparesthesia), decreased sweating (hypohidrosis), and gastrointestinal distress. As the disease progresses into adulthood, the chronic accumulation of Gb3 leads to irreversible organ damage. Patients frequently face chronic kidney disease that can progress to end-stage renal failure, hypertrophic cardiomyopathy, and an increased risk of premature stroke.
For decades, the standard of care has been bi-weekly intravenous infusions of enzyme replacement therapy. While effective at slowing disease progression, the requirement for frequent, hours-long clinic visits creates a significant logistical and emotional burden for patients. Furthermore, the "peak and valley" pharmacokinetic profile of traditional ERTs can lead to suboptimal Gb3 clearance in certain tissues.
Next-Generation Mechanism: HM15421/GC1134A and Subcutaneous Dosing
The investigational candidate HM15421/GC1134A is designed to address the shortcomings of first-generation ERTs through advanced protein engineering. The therapy is a recombinant human alpha-Gal A that has been modified to extend its half-life and enhance its molecular stability. These improvements are critical because they enable the drug to be administered via subcutaneous injection rather than intravenous infusion.
Subcutaneous administration represents a paradigm shift in the delivery of enzyme therapies. It offers the potential for home-based self-administration, which would drastically reduce the time patients spend in medical facilities. BioMarin has noted that preclinical data for HM15421/GC1134A showed robust efficacy across several critical biomarkers. In animal models, the drug demonstrated the ability to maintain stable enzyme levels in the blood, leading to significant reductions in Gb3 levels in the kidneys and heart. Additionally, research indicated improvements in vascular health and peripheral nervous system outcomes, suggesting that the long-acting nature of the therapy might provide more consistent cellular protection than existing treatments.
While the specific dosing interval for human trials has not yet been finalized, the goal is to provide a schedule that is significantly less frequent than the current bi-weekly standard. GC Biopharma and Hanmi Pharm have already initiated a global Phase 1/2 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of the drug in humans. BioMarin will assume control of the program following the conclusion of this ongoing study.
Synergy with BioMarin’s Existing Rare Disease Infrastructure
BioMarin is no stranger to the complexities of enzyme replacement therapy. The company has built its reputation on developing treatments for ultra-rare conditions, including Morquio A syndrome (Vimizim), Maroteaux-Lamy syndrome (Naglazyme), and CLN2 disease (Brineura). The addition of HM15421/GC1134A brings BioMarin’s total number of enzyme therapies to eight, further solidifying its dominant position in the lysosomal storage disorder market.
The financial performance of Galafold provides a clear indicator of the market potential for Fabry treatments. In 2025, Galafold generated $521.7 million in global sales, marking a 14% year-over-year increase. However, the ceiling for Galafold is inherently limited by the genetic profile of the patient population. By adding a next-generation ERT to its stable, BioMarin can offer a "total solution" for Fabry disease: Galafold for the 30-40% of patients with amenable mutations, and HM15421/GC1134A for the remaining 60-70% who require exogenous enzyme replacement.
Lachlan Hanbury-Brown, an analyst at William Blair, commented on the deal, noting that the acquisition is a logical extension of BioMarin’s current footprint. "This acquisition makes sense given the company’s current expertise in ERTs and global capabilities to drive a potential successful launch," Hanbury-Brown stated. He emphasized that the ability to treat the broader Fabry population significantly increases BioMarin’s addressable market and creates synergies with their existing sales and medical affairs teams already focused on the disease.
Competitive Landscape and the Evolution of Fabry Care
The Fabry disease market is currently served by several major pharmaceutical players, but it is undergoing a period of rapid evolution. Sanofi’s Fabrazyme and Chiesi Group’s Elfabrio are the primary competitors in the U.S. ERT market. Takeda’s Replagal also holds a significant share of the market in Europe and Japan, though it has never received FDA approval in the United States. All three of these products require bi-weekly intravenous infusions.
The entry of HM15421/GC1134A could disrupt this status quo by offering a more patient-friendly delivery method. However, ERTs are not the only modality on the horizon. The industry is also closely watching the development of gene therapies, which promise a potential "one-and-done" cure.
In a notable development earlier in 2026, PTC Therapeutics acquired the Fabry gene therapy program ST-920 from Sangamo Therapeutics during a bankruptcy auction. PTC has moved aggressively with this program, completing its acquisition in September 2026. ST-920 is currently in a rolling submission process with the FDA, with completion expected by the end of the fourth quarter. If approved, gene therapy would offer an alternative that eliminates the need for regular enzyme replacement or chaperone therapy altogether. BioMarin’s investment in a next-generation ERT suggests that the company believes there will remain a significant market for high-quality, long-acting enzyme therapies even as gene therapies enter the fray, perhaps for patients who are ineligible for gene therapy due to pre-existing antibodies or those who prefer a non-genetic intervention.
Chronology of BioMarin’s Fabry Expansion and Market Trajectory
The timeline of BioMarin’s recent maneuvers highlights a rapid and aggressive expansion strategy:
- Early 2025: BioMarin completes the $4.8 billion acquisition of Amicus Therapeutics, gaining the commercial-stage drug Galafold.
- Mid-2025: Galafold reports record annual sales of $521.7 million, proving the commercial viability of the Fabry market.
- Late 2025: BioMarin begins internal assessments to fill the "non-amenable" patient gap in its portfolio.
- December 2025: BioMarin enters into the exclusive licensing agreement with GC Biopharma and Hanmi Pharm for HM15421/GC1134A.
- 2026 and Beyond: BioMarin is expected to transition the Phase 1/2 data into a pivotal Phase 3 program, aiming for global regulatory filings to challenge the dominance of IV-infused ERTs.
Economic Implications and Analyst Outlook
The $70 million upfront payment is considered a disciplined expenditure for a company of BioMarin’s size, especially given the clinical stage of the asset. By structuring the deal with over $400 million in back-ended milestones, BioMarin has mitigated its risk while securing a high-potential asset.
The broader implications for the rare disease market are clear: the focus is shifting from simply providing an enzyme to optimizing the patient experience. The move toward subcutaneous dosing and extended half-lives is a response to the growing demand for "patient-centric" medicine. If BioMarin can successfully navigate the regulatory hurdles for HM15421/GC1134A, they could potentially set a new benchmark for ERT administration.
Industry observers suggest that BioMarin’s move may trigger further consolidation or licensing deals in the rare disease space as companies scramble to update their aging ERT portfolios. For now, BioMarin appears to have secured a strategic advantage, leveraging its historical expertise in enzyme science and its newly acquired commercial strength in Fabry disease to build a moat around one of the most lucrative segments of the orphan drug market.
